Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
This guide highlights when your current budgeting approach may be failing and offers practical signs to rethink it. Learn how to reset goals and reallocate spending.
21,437 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
When a big fund trims a REIT stake, investors watch for clues about rental income and stock performance. This article...
UiPath faced a cautious session as its Korea cloud launch tests regional demand. This article breaks down what happen...
Perplexity's CEO argues that embracing the risk of idea theft keeps a fast-moving AI startup on its toes. The comment...
A Roth conversion ladder is drawing renewed interest as a way for a 55-year-old with $1.4 million to bridge to Social...
This guide helps investors decode Workiva's 2025 earnings landscape. Learn which metrics matter, how to read manageme...
Despite a 2026 pullback, Advanced Micro Devices still shows fundamental strength in data-center AI demand and a diver...
A $50,000 retirement target split 50/50 between REIT dividends and stock dividends changes the math. Today, investors...
Rivian's R2 rollout marks a new chapter for the EV maker. This guide breaks down whether the stock deserves a place i...
Palantir has volatile days, but one wall street analyst believes the stock could double within a year. This article b...
A new, sizable stake in Cal-Maine Foods hints at investor conviction despite a halved income last quarter. This piece...
Investor nerves rose as here's gemini space station faced a sharp price drop this week. This piece breaks down what s...